Skip to main content

Table 4 Comorbidities of patients hospitalized who underwent a bioprosthetic mitral valve replacement in Spain from 2001 to 2015 according to type 2 diabetes status

From: Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001–2015)

  T2DM 2001–2005 2006–2010 2011–2015 Total Trend
Mitral stenosis, n (%) Yes 15 (6.85) 23 (5.12) 37 (5.9) 75 (5.79) 0.660
No 67 (5.91) 96 (5.06) 109 (4.03) 272 (4.74) 0.032
Rheumatic mitral insufficiency, n (%) Yes 8 (3.65) 12 (2.67) 20 (3.19) 40 (3.09) 0.773
No 28 (2.47) 87 (4.58) 82 (3.03) 197 (3.43) 0.002
Mitral stenosis with insufficiency, n (%) Yes 25 (11.42) 55 (12.25) 58 (9.25) 138 (10.66) 0.268
No 109 (9.61) 187 (9.85) 238 (8.8) 534 (9.31) 0.442
Charlson Comorbidity Index, mean (SD) Yes 1.05 (0.88) 0.96 (0.79) 1.12 (0.85) 1.05 (0.83) 0.167
No 0.87 (0.78) 0.98 (0.8) 1.06 (0.86) 0.99 (0.83) < 0.001
Chronic obstructive pulmonary disease, n (%) Yes 27 (12.33) 40 (8.91) 52 (8.29) 119 (9.19) 0.199
No 81 (7.14) 130 (6.85) 218 (8.06) 429 (7.48) 0.276
Peripheral vascular disease, n (%) Yes 7 (3.2) 16 (3.56) 32 (5.1) 55 (4.25) 0.326
No 43 (3.79) 101 (5.32) 142 (5.25) 286 (4.98) 0.119
Acute renal disease, n (%) Yes 31 (14.16) 80 (17.82) 128 (20.41) 239 (18.46) 0.110
No 145 (12.79) 318 (16.75) 575 (21.25) 1038 (18.09) < 0.001
Cerebrovascular disease, n (%) Yes 11 (5.02) 19 (4.23) 33 (5.26) 63 (4.86) 0.735
No 47 (4.14) 102 (5.37) 155 (5.73) 304 (5.3) 0.134
Congestive heart failure, n (%) Yes 64 (29.22) 114 (25.39) 185 (29.51) 363 (28.03) 0.304
No 287 (25.31) 519 (27.34) 818 (30.23) 1624 (28.3) 0.004
Atrial fibrillation, n (%) Yes 113 (51.6) 253 (56.35) 377 (60.13) 743 (57.37) 0.077
No 562 (49.56) 1078 (56.8) 1587 (58.65) 3227 (56.24) < 0.001
Pulmonary hypertension, n (%) Yes 66 (30.14) 133 (29.62) 195 (31.1) 394 (30.42) 0.869
No 271 (23.9) 564 (29.72) 791 (29.23) 1626 (28.34) 0.001
Coronary artery disease, n (%)* Yes 87 (39.73) 165 (36.75) 229 (36.52) 481 (37.14) 0.684
No 297 (26.19) 508 (26.77) 727 (26.87) 1532 (26.7) 0.908
Obesity, n (%)* Yes 26 (11.87) 43 (9.58) 87 (13.88) 156 (12.05) 0.102
No 39 (3.44) 85 (4.48) 162 (5.99) 286 (4.98) 0.002
Cardiogenic shock, n (%) Yes 11 (5.02) 22 (4.9) 23 (3.67) 56 (4.32) 0.530
No 67 (5.91) 106 (5.58) 144 (5.32) 317 (5.52) 0.761
Endocarditis, n (%) Yes 32 (14.61) 74 (16.48) 123 (19.62) 229 (17.68) 0.176
No 154 (13.58) 337 (17.76) 618 (22.84) 1109 (19.33) < 0.001
Pneumonia, n (%) Yes 6 (2.74) 17 (3.79) 15 (2.39) 38 (2.93) 0.403
No 59 (5.2) 63 (3.32) 104 (3.84) 226 (3.94) 0.034
Renal disease, n (%)* Yes 20 (9.13) 45 (10.02) 99 (15.79) 164 (12.66) 0.004
No 73 (6.44) 153 (8.06) 305 (11.27) 531 (9.25) < 0.001
Liver disease, n (%) Yes 7 (3.2) 12 (2.67) 27 (4.31) 46 (3.55) 0.344
No 39 (3.44) 65 (3.42) 119 (4.4) 223 (3.89) 0.167
Cancer, n (%) Yes 4 (1.83) 6 (1.34) 4 (0.64) 14 (1.08) 0.278
No 10 (0.88) 27 (1.42) 38 (1.4) 75 (1.31) 0.371
Weight loss, n (%) Yes 0 (0) 1 (0.22) 4 (0.64) 5 (0.39) 0.334
No 3 (0.26) 7 (0.37) 11 (0.41) 21 (0.37) 0.802
  1. T2DM type 2 diabetes mellitus
  2. * p < 0.05 for comparisons between T2DM patients and non-T2DM patients